TFS Capital’s Theravance Biopharma TBPH Stock Holding History

TFS Capital’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-47,803	Closed	-$1.08M	–	973
2016 Q2	$1.08M	Buy	+47,803	New	+$1.03M	0.2%	156

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TFS Capital's TBPH Position: Q3 2016 in Review

TFS Capital sold out of Theravance Biopharma (TBPH) in Q3 2016, closing a stake of 47,803 shares — an estimated $1.08M sold.

TFS Capital first reported a position in TBPH in Q2 2016 and held it in 1 quarter. The position peaked at $1.08M in Q2 2016. 100 funds tracked by Wall St. Rank hold TBPH as of Q3 2016.

TFS Capital reported no remaining Theravance Biopharma position as of Q3 2016 after selling out during the quarter.
TFS Capital sold 47,803 Theravance Biopharma shares in Q3 2016, an estimated $1.08M.
TFS Capital first reported a position in Theravance Biopharma in Q2 2016 and held it in 1 quarter.
TFS Capital's Theravance Biopharma position peaked at $1.08M in Q2 2016.
100 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2016.

Based on TFS Capital's 13F filing for Q3 2016, filed 10 Nov 2016.